| 0.6402 -0.05 (-7.22%) | 08-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.22  |
1-year : | 1.57 |
| Resists | First : | 1.05 |
Second : | 1.35 |
| Pivot price | 0.75 |
|||
| Supports | First : | 0.56 |
Second : | 0.47 |
| MAs | MA(5) : | 0.69 |
MA(20) : | 0.82 |
| MA(100) : | 1.4 |
MA(250) : | 1.6 |
|
| MACD | MACD : | -0.2  |
Signal : | -0.2 |
| %K %D | K(14,3) : | 6.6 |
D(3) : | 6.2 |
| RSI | RSI(14): 28.8 |
|||
| 52-week | High : | 2.44 | Low : | 0.56 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BYSI ] has closed above bottom band by 15.2%. Bollinger Bands are 17.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.7 - 0.7 | 0.7 - 0.7 |
| Low: | 0.56 - 0.56 | 0.56 - 0.56 |
| Close: | 0.63 - 0.64 | 0.64 - 0.65 |
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
Fri, 14 Aug 2026
BeyondSpring Inc. (BYSI) founders disclose 5.29M shares each in 13G/A - Stock Titan
Fri, 14 Aug 2026
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
Thu, 02 Jul 2026
BeyondSpring Inc. (BYSI) Edges Higher with Modest Gains, Testing Key Resistance Levels - Regression Channel - dars.gov.et
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 41 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 14.2 (%) |
| Held by Institutions | 14.8 (%) |
| Shares Short | 2,240 (K) |
| Shares Short P.Month | 2,220 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.88 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | 11 (M) |
| PE Ratio | -3.56 |
| PEG Ratio | 0 |
| Price to Book value | -0.74 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|